Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 10/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482864 | 0.94 | CYP11B1 (0.36) | GLP1RCYP11B1CYP11B2PDE10AKCNH2 | |
| SCHEMBL1483043 | 0.93 | NR1H4 (0.37) | GLP1RPTGER1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL1482427 | 0.93 | NR1H4 (0.36) | GLP1RCYP11B1CYP11B2PDE10AKCNH2 | |
| SCHEMBL1482217 | 0.92 | NR1H4 (0.38) | GLP1RPTGER1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL1482279 | 0.88 | GLP1R (0.42) | GLP1RCNR2PDE10AKCNH2HTR1A | |
| SCHEMBL1482910 | 0.88 | GLP1R (0.39) | GLP1RPTGER1PDE10AKCNH2HTR1A | |
| SCHEMBL1482770 | 0.84 | KCNH2 (0.41) | CYP11B1CYP11B2KCNH2KDM1A | |
| SCHEMBL1482742 | 0.84 | NPSR1 (0.43) | KCNH2 | |
| SCHEMBL1482840 | 0.84 | CYP11B2 (0.34) | CNR1CYP11B1CYP11B2PDE2A | |
| SCHEMBL1482680 | 0.83 | MDM2 (0.39) | CNR1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | GLP1R 451/4885RORC 2047/4885CNR1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.